No Data
Adhera Therapeutics, Now on OTCQB, Files to Offer Stock and Warrants and Seeks Nasdaq Capital Market Listing >ATRX
Adhera Therapeutics Announces Appointed Zahed Subhan PhD MBA JD As CEO, Senior Management Changes, Plans For NASDAQ Uplist
Adhera Therapeutics signs letter of intent to acquire cancer therapy
Adhera Therapeutics Signs Letter Of Intent To Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin >ATRX
Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq
Adhera Therapeutics provides update on mid-stage MLR-1019 Parkinson’s disease trial